Fig. 3From: Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in ItalyResults of one-way deterministic sensitivity analysis. VA Visual Acuity, WSE worse seeing eyeBack to article page